Table 2. End of treatment and sustained virological responses.
| HCV RNA <LLOQa | All patients (N = 492) | Age 65–74 years (N = 278) | Age ≥ 75 (N = 214) | P Value | |||
|---|---|---|---|---|---|---|---|
| n/N (%) | 95% CI | n/N (%) | 95% CI | n/N (%) | 95% CI | ||
| End of Treatment Response (ETVR) | |||||||
| Per Protocol Analysis | 476 / 479 (99.4) | 98.2–99.9 | 268 / 270 (99.3) | 97.4–99.9 | 208 / 209 (99.5) | 97.3–100 | 1.000 |
| Intention to Treat | 477 / 492 (97.0) | 95.1–98.3 | 269 / 278 (96.8) | 94.0–98.5 | 208 / 214 (97.2) | 94–99 | 0.990 |
| Sustained Response (SVR) | |||||||
| Per Protocol Analysis | 473 / 476 (99.4) | 98.2–99.9 | 267 / 269 (99.3) | 97.4–99.9 | 206 / 207 (99.5) | 97.3–100 | 1.000 |
| Intention to Treat | 476 / 492 (96.7) | 94.7–98.1 | 269 / 278 (96.8) | 94.0–98.5 | 207 / 214 (96.7) | 93.3–98.7 | 1.000 |
Notes.
a
LLOQ, lower limit of qualification is 12 IU/mL